Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors.
Autopsy
Body mass index
COVID-19
Hereditary thrombophilia
Intensive care unit
Thromboembolism
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
26
03
2022
revised:
11
08
2022
accepted:
19
08
2022
pubmed:
4
9
2022
medline:
21
9
2022
entrez:
3
9
2022
Statut:
ppublish
Résumé
Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) results in respiratory syndromes but also in vascular complications such as thromboembolism (TE). In this regard, immunothrombosis, resulting from inflammation in SARS-CoV-2 infected tissues, has been described. Data on TE in COVID-19 are mainly based on clinical observational and/or incomplete autopsy studies. The true burden of TE and the relevance of genetic predisposition, however, have not been resolved. Here, we report on a consecutive cohort of 100 fully autopsied patients deceased by SARS-CoV-2 infections during the first wave of the pandemic (March to April 2020). We investigated the localization of TE, potential clinical risk factors, and the prothrombotic gene mutations, factor V Leiden and prothrombin G20210A, in postmortem blood or tissue samples. TE was found in 43/100 autopsies. 93 % of TE events were venous occlusions, with 23 patients having pulmonary thromboembolism (PT) with or without lower-extremity deep vein thrombosis. Of these, 70 % showed PT restricted to (sub)segmental arteries, consistent with in situ immunothrombosis. Patients with TE had a significantly higher BMI and died more frequently at an intensive care unit. Hereditary thrombophilia factors were not associated with TE. Our autopsy results show that a significant proportion of SARS-CoV-2 infected patients suffer from TE, affecting predominantly the venous system. Orthotopic peripheral PT was the most frequent finding. Hereditary thrombophilia appears not to be a determinant for TE in COVID-19. However, obesity and the need for intensive care increase the risk of TE in these patients.
Sections du résumé
BACKGROUND
Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) results in respiratory syndromes but also in vascular complications such as thromboembolism (TE). In this regard, immunothrombosis, resulting from inflammation in SARS-CoV-2 infected tissues, has been described. Data on TE in COVID-19 are mainly based on clinical observational and/or incomplete autopsy studies. The true burden of TE and the relevance of genetic predisposition, however, have not been resolved.
OBJECTIVES
Here, we report on a consecutive cohort of 100 fully autopsied patients deceased by SARS-CoV-2 infections during the first wave of the pandemic (March to April 2020). We investigated the localization of TE, potential clinical risk factors, and the prothrombotic gene mutations, factor V Leiden and prothrombin G20210A, in postmortem blood or tissue samples.
RESULTS
TE was found in 43/100 autopsies. 93 % of TE events were venous occlusions, with 23 patients having pulmonary thromboembolism (PT) with or without lower-extremity deep vein thrombosis. Of these, 70 % showed PT restricted to (sub)segmental arteries, consistent with in situ immunothrombosis. Patients with TE had a significantly higher BMI and died more frequently at an intensive care unit. Hereditary thrombophilia factors were not associated with TE.
CONCLUSIONS
Our autopsy results show that a significant proportion of SARS-CoV-2 infected patients suffer from TE, affecting predominantly the venous system. Orthotopic peripheral PT was the most frequent finding. Hereditary thrombophilia appears not to be a determinant for TE in COVID-19. However, obesity and the need for intensive care increase the risk of TE in these patients.
Identifiants
pubmed: 36057167
pii: S0049-3848(22)00363-2
doi: 10.1016/j.thromres.2022.08.021
pmc: PMC9420077
pii:
doi:
Substances chimiques
Prothrombin
9001-26-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-176Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Thromb Haemost. 2014 Sep;12(9):1391-400
pubmed: 24954194
Anaesthesist. 2021 Dec;70(Suppl 1):19-29
pubmed: 33245382
Lancet Reg Health Eur. 2022 Feb 18;15:100330
pubmed: 35531493
Hamostaseologie. 2020 Aug;40(3):264-269
pubmed: 32498097
Crit Care Med. 2021 Jul 1;49(7):e663-e672
pubmed: 33861545
Blood Adv. 2021 Feb 9;5(3):872-888
pubmed: 33560401
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
BMJ. 2022 Apr 6;377:e069590
pubmed: 35387772
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Vascul Pharmacol. 2021 Aug;139:106882
pubmed: 34087481
Ann Vasc Surg. 2021 Jan;70:290-294
pubmed: 32866580
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Nutrients. 2021 Sep 28;13(10):
pubmed: 34684447
N Engl J Med. 2013 Aug 29;369(9):799-808
pubmed: 23808982
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Res Pract Thromb Haemost. 2020 Oct 13;4(7):1178-1191
pubmed: 33043231
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223
Lancet Infect Dis. 2022 Jul;22(7):967-976
pubmed: 35468331
Front Public Health. 2020 Aug 04;8:432
pubmed: 32903841
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Thromb Haemost. 2015 Nov;114(5):885-9
pubmed: 26018405
J Thromb Haemost. 2021 Apr;19(4):1038-1048
pubmed: 33534149
Inflamm Res. 2020 Dec;69(12):1181-1189
pubmed: 32918567
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Int J Legal Med. 2020 Jul;134(4):1275-1284
pubmed: 32500199
Cardiovasc Res. 2017 Jul 1;113(9):1046-1054
pubmed: 28472252
J Am Coll Cardiol. 2020 Nov 3;76(18):2060-2072
pubmed: 33121712
Ann Intern Med. 2020 Sep 1;173(5):350-361
pubmed: 32422076
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Virchows Arch. 2017 Oct;471(4):491-500
pubmed: 28812131
Histopathology. 2020 Aug;77(2):198-209
pubmed: 32364264
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Vasa. 2020 Jun;49(4):259-263
pubmed: 32501145